Plus   Neg

Occidental Petroleum Slips To Loss In Q1; Cuts Capital Budget Again

Occidental Petroleum Corp. (OXY) reported a first-quarter net loss attributable to common stockholders of $2.23 billion or $2.49 per share, compared to net income of $631 million or $0.84 per share in the prior year.

The latest-quarter results included approximately $1.4 billion of goodwill impairment charges and equity investment losses mainly related to an equity investment in Western Midstream Partners, LP, $670 million mark-to-market loss on interest rate swaps, $580 million of impairment and related charges on domestic and international oil and gas properties and $150 million of Anadarko acquisition-related transaction costs, partially offset by $1.0 billion of mark-to-market gains on crude oil hedges.

Adjusted loss attributable to common stockholders was $467 million, or $0.52 per share, compared to net income of $631 million or $0.84 per share in the prior year. Analysts polled by Thomson Reuters expected the company to report a loss of $0.63 per share. Analysts' estimates typically exclude special items.

Revenues and other income grew to $6.45 billion from $4.09 billion last year. Analysts expected revenue of $5.18 billion for the quarter.

The company said it has identified an additional $1.2 billion in operating and corporate cost savings and reduced its full-year capital budget to between $2.4 billion to $2.6 billion, while protecting the integrity of its assets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. on Friday unlocked the New York Post's Twitter account after a two-week stalemate over posting links to its reporting about Hunter Biden. Walmart has removed guns and ammunition from its store shelves in the U.S. as a precautionary measure following the unrest in Philadelphia after a Black man was fatally shot by police, according to reports. While the firearms will be available for purchase at the Walmart stores, customers will be required to specifically request for them. Regeneron Pharmaceuticals Inc. (REGN) said Friday that the independent data monitoring committee or IDMC for the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended to hold further enrollment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.
Follow RTT